title: Outlining novel cellular adjuvant products for therapeutic vaccines against cancer.
abstract: Despite the library of new adjuvants available for use in vaccines, we remain, at present, almost reliant on aluminum-based compounds for clinical use. The increasing use of recombinant subunit vaccines, however, makes the need for improved adjuvant of particular interest. Adjuvants are crucial components of all cancer vaccines whether they are composed of whole cells, proteins or peptides. For the purposes of this article, cellular adjuvant products are defined as adjuvants associated with cellular or T-cell immunity. Several pharmaceutical companies are developing new adjuvants or immune enhancers for the treatment of cancers such as melanoma and non-small-cell lung carcinoma. Several products are being developed and have entered clinical trials either alone or in combination. In this article, we discuss recent adjuvant development and novel cellular adjuvant products for therapeutic cancer vaccines.
authors.affiliation: Wittycell, Pépinière Genopole Entreprises, Campus 3-4, rue Pierre Fontaine, 91058 EVRY Cedex, France. jnitcheu@wittycell.com
authors.forename: Josianne Nitcheu
authors.initials: JN
authors.lastname: Tefit
authors.forename: Vincent
authors.initials: V
authors.lastname: Serra
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology; D009369:Neoplasms / Q000276:immunology / Q000517:prevention & control / Q000628:therapy*; D022223:Vaccines, Subunit / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic